IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
1 hedge funds and large institutions have $508 invested in IGM Biosciences in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 65 closing their positions.
45.9% less ownership
Funds ownership: 45.9% → 0% (-46%)
98% less funds holding
Funds holding: 66 → 1 (-65)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $17.9M → $508 (-$17.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 65
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.59M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$3.65M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$3.31M |
| 4 |
S
Sanofi
Paris,
France
|
-$1.61M |
| 5 |
Goldman Sachs
New York
|
-$958K |
IGMS Hedge Fund Activity: Q3 2025 in Review
1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2025, worth a combined $508 — down 100% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of IGMS and 0 opened new positions — a net loss of 65 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.59M sold.
- 1 institutional investor held IGM Biosciences (IGMS) as of Q3 2025, down from 66 in Q2 2025.
- Funds reported $508 of IGM Biosciences stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new IGM Biosciences positions in Q3 2025 and 65 closed out, a net change of -65 holders.
- The largest IGM Biosciences seller in Q3 2025 was Baker Bros. Advisors, an estimated $4.59M sold.
Based on aggregated 13F filings for Q3 2025.